- Home
- Products
- Customized ADCs
- MUC16
- Anti-MUC16-BMPEO-DM1 ADC-1
Anti-MUC16-BMPEO-DM1 ADC-1 (CAT#: ADC-W-154)
This ADC product is comprised of an anti-MUC16 monoclonal antibody (clone 3A5) conjugated via a BMPEO linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, DM1 binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- Product Information
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Antibody clone #
- 3A5
- Name
- MUC16
- Alternative Names
- CA125
- Target Entrez Gene ID
- 94025
- Target UniProt ID
- B3KY81
- Overview
- MUC16 is a Protein Coding gene. Diseases associated with MUC16 include mucinous ovarian cystadenoma and pleural cancer. Among its related pathways are Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein and Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein.
- Overview
- Anti-MUC16 antibody, clone # 3A5
- Clone #
- 3A5
- Name
- BMPEO (bis-maleimido-trioxyethylene glycol)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
- Description
- Derived from Maytansinoid,a group of cytotoxins structurally similar to rifamycin, geldanamycin, and ansatrienin. The eponymous natural cytotoxic agent maytansine is a 19-member lactam (ansa
macrolide) structure originally isolated from the Ethiopian shrub Maytenus ovatus. Maytansinoids can bind to tubulin at or near the vinblastine-binding site, which interfere the formation of microtubules and depolymerize already formed microtubules, inducing mitotic arrest in the intoxicated cells.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-CD22-AcBut-CalichDMH ADC-10 (CAT#: ADC-W-461)
- Anti-TNFRSF8 (Iratumumab)-MC-MMAF ADC (CAT#: ADC-W-1888)
- Anti-IGHE (Ligelizumab)-SMCC-DM1 ADC (CAT#: ADC-W-1280)
- Anti-CEACAM5 (Altumomab)-SMCC-DM1 ADC (CAT#: ADC-W-968)
- Anti-ERBB2-Mc-VC-PABC-MMAE ADC (CAT#: ADC-W-607)
- Anti-CD3E (Visilizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-845)
- Anti-SOST (Blosozumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1769)
- Anti-ITGA2 (Vatelizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1459)
- Anti-APP (Ponezumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-715)
- Anti-IGF2 (Dusigitumab)-MC-MMAF ADC (CAT#: ADC-W-1270)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-154. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1644 | Anti-MUC16 (Igovomab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-2569 | Anti-MUC16 (Sofituzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-564 | Anti-MUC16-VC-MMAE ADC | VC (valine-citrulline) | MMAE (Monomethyl auristatin E) |
| ADC-W-1646 | Anti-MUC16 (Oregovomab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1648 | Anti-MUC16 (Oregovomab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-W-152 | Anti-ERBB2-BMPEO-DM1 ADC | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-028 | Anti-CD79b-BMPEO-DM1 ADC-2 | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-177 | Anti-CD22-BMPEO-DM1 ADC-2 | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-151 | Anti-ERBB2-BMPEO-DM1 ADC-1 | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-025 | Anti-CD79b-BMPEO-DM1 ADC-1 | BMPEO (bis-maleimido-trioxyethylene glycol) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-495 | Anti-EGFR-SMCC-DM1 ADC-4 | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-AA-018 | anti-HIgG(Fab)-N-DM1 ADC | Noncleavable linkers | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-582 | Anti-ERBB2-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-460 | Anti-NCAM1-SPP-DM1 ADC | SPP (N-succinimidyl-4-(2-pyridyldithio)pentanoate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-AA-015 | anti-HIgG(Fc)Fab-N-DM1 ADC | Noncleavable linkers | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.